title: Increase resistant rates and ESBL production between E. coli isolates causing urinary tract infection in young patients from Iran.
abstract: Emerging antimicrobial resistance rates and Extended-spectrum beta-lactamase producing Escherichia coli recovered from urinary tract infections (UTI) is an increasing problem in specific regions, limiting therapeutic options. One hundred E. coli isolates causing UTI in patients with age from 2 months to 12 years admitted at CMC in the period of April 2009 to March 2010 were tested for antibiotic susceptibility using the disk diffusion method. Surprisingly high resistance rates were recorded for E. coli against TMP/SMX (84%), cefalotin (66%), cefuroxime (50%), cefixime (50%) and ceftriaxone (45%). Antimicrobial susceptibility of E. coli isolates was followed by meropenem (98%), amikacin (95%), nitrofurantoin (91%) and gentamicin (68%). Extended spectrum beta-lactamase production, was observed in 32% of community and 42% of nosocomial isolates. The results of this study and numerous observations regarding the increasing resistance to these antibiotics, in several countries, emphasize the need for local population-specific surveillance for guiding empirical therapy for UTI in children.
authors.affiliation: Pediatrics Infectious Diseases Research Center, Tehran University of Medical Sciences , Tehran , Iran.
authors.forename: Babak
authors.initials: B
authors.lastname: Pourakbari
authors.forename: Farzad
authors.initials: F
authors.lastname: Ferdosian
authors.forename: Shima
authors.initials: S
authors.lastname: Mahmoudi
authors.forename: Mostafa
authors.initials: M
authors.lastname: Teymuri
authors.forename: Farah
authors.initials: F
authors.lastname: Sabouni
authors.forename: Hossein
authors.initials: H
authors.lastname: Heydari
authors.forename: Mohammad Taghi Haghi
authors.initials: MT
authors.lastname: Ashtiani
authors.forename: Setareh
authors.initials: S
authors.lastname: Mamishi
keywords: Antimicrobial susceptibility; E. coli; ESBL; Urinary Tract Infection
references.citation: Ital J Pediatr. 2011 Jan 06;37:3
references.pmid: 21211026
references.citation: Jpn J Infect Dis. 2006 Dec;59(6):380-2
references.pmid: 17186957
references.citation: Arch Dis Child. 2003 May;88(5):444-5
references.pmid: 12716722
references.citation: Iran J Kidney Dis. 2008 Oct;2(4):197-200
references.pmid: 19377237
references.citation: Emerg Infect Dis. 2002 Mar;8(3):278-82
references.pmid: 11927025
references.citation: Clin Microbiol Infect. 2008 Jan;14 Suppl 1:144-53
references.pmid: 18154538
references.citation: Ann Clin Microbiol Antimicrob. 2007 Mar 23;6:4
references.pmid: 17378940
references.citation: Antimicrob Agents Chemother. 1989 Aug;33(8):1131-6
references.pmid: 2679367
references.citation: J Antimicrob Chemother. 2005 Nov;56(5):914-8
references.pmid: 16174685
references.citation: Mem Inst Oswaldo Cruz. 2006 Nov;101(7):741-8
references.pmid: 17160281
references.citation: Am J Emerg Med. 2012 Jul;30(6):942-9
references.pmid: 21802879
references.citation: Scand J Infect Dis. 2010 Apr;42(4):243-8
references.pmid: 20085420
references.citation: J Antimicrob Chemother. 2007 Feb;59(2):309-12
references.pmid: 17138569
references.citation: Eur J Clin Microbiol Infect Dis. 2007 Feb;26(2):83-90
references.pmid: 17235554
references.citation: J Infect Dev Ctries. 2010 May 01;4(4):202-6
references.pmid: 20440056
references.citation: J Antimicrob Chemother. 2005 Jul;56(1):236-9
references.pmid: 15890716
references.citation: Chemotherapy. 2009;55(2):127-31
references.pmid: 19188712
references.citation: Antimicrob Agents Chemother. 2004 Jan;48(1):1-14
references.pmid: 14693512
references.citation: Infect Dis Clin North Am. 2003 Jun;17(2):243-59
references.pmid: 12848469
references.citation: Clin Microbiol Infect. 2008 Jan;14 Suppl 1:134-43
references.pmid: 18154537
references.citation: Pediatr Nephrol. 2010 May;25(5):919-25
references.pmid: 20151161